Does regulating against possible harm leave Europe behind on innovation?
Core argument: The McKinsey Global Institute found that among companies with more than $1 billion in revenue, U.S. firms spent 80% more on research and development, earned 30% higher return on capital, and grew revenue 1.3 percentage points faster than European peers.
Europe’s economy underperforms for lots of reasons, from demographics to energy costs, not just regulation. And U.S. regulators aren’t exactly hands-off. Still, they tend to act on evidence of harm, whereas Europe’s will act on the mere possibility. This precautionary principle can throttle innovation in its cradle. The McKinsey Global Institute noted Europe’s internal market is larger than China’s and almost as big as the U.S.’s. But when it compared companies with more than $1 billion in revenue, the U.S. firms spent 80% more on research and development, boasted 30% higher return on capital, and 1.3-percentage points faster revenue growth.




